Viral-derived Serp-1 as an adjunctive therapy for percutaneous coronary intervention: another not ready for prime time player?
作者信息
Leopold Jane A
出版信息
Circ Cardiovasc Interv. 2010 Dec;3(6):528-30. doi: 10.1161/CIRCINTERVENTIONS.110.959684.
Abstract
摘要
相似文献
1
Viral-derived Serp-1 as an adjunctive therapy for percutaneous coronary intervention: another not ready for prime time player?病毒衍生的Serp-1作为经皮冠状动脉介入治疗的辅助疗法：又一个尚未准备好成为主要疗法的手段？
Circ Cardiovasc Interv. 2010 Dec;3(6):528-30. doi: 10.1161/CIRCINTERVENTIONS.110.959684.
2
A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention.一项在接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者中进行的病毒丝氨酸蛋白酶抑制剂 Serp-1 的随机对照、2 期临床试验。
Circ Cardiovasc Interv. 2010 Dec;3(6):543-8. doi: 10.1161/CIRCINTERVENTIONS.110.953885. Epub 2010 Nov 9.
3
Viral serine proteinase inhibitor (SERP-1) effectively decreases the incidence of graft vasculopathy in heterotopic heart allografts.病毒丝氨酸蛋白酶抑制剂（SERP-1）可有效降低异位心脏移植中移植物血管病变的发生率。
Transplantation. 2001 Aug 15;72(3):364-8. doi: 10.1097/00007890-200108150-00003.
4
Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty.病毒编码的丝氨酸蛋白酶抑制剂SERP-1可抑制球囊血管成形术后动脉粥样硬化斑块的发展。
Circulation. 1996 Dec 1;94(11):2890-900. doi: 10.1161/01.cir.94.11.2890.
5
The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics.丝氨酸蛋白酶抑制剂传奇；新型病毒衍生抗炎蛋白免疫治疗药物的研发。
Adv Exp Med Biol. 2009;666:132-56. doi: 10.1007/978-1-4419-1601-3_11.
6
Amelioration of antigen induced arthritis in rabbits treated with a secreted viral serine proteinase inhibitor.用分泌型病毒丝氨酸蛋白酶抑制剂治疗的兔抗原诱导性关节炎的改善情况。
J Rheumatol. 1996 May;23(5):878-82.
7
Can a viral serine proteinase inhibitor prevent postangioplasty restenosis?一种病毒丝氨酸蛋白酶抑制剂能否预防血管成形术后再狭窄？
Circulation. 1996 Dec 1;94(11):2694-5. doi: 10.1161/01.cir.94.11.2694.
8
Serpins for diagnosis and therapy in cancer.用于癌症诊断和治疗的丝氨酸蛋白酶抑制剂
Cardiovasc Hematol Disord Drug Targets. 2013 Aug;13(2):123-32. doi: 10.2174/1871529x11313020005.
9
Radial approach for primary percutaneous coronary intervention: ready for prime time?用于直接经皮冠状动脉介入治疗的桡动脉途径：准备好进入黄金时代了吗？
J Am Coll Cardiol. 2012 Dec 18;60(24):2500-3. doi: 10.1016/j.jacc.2012.09.019.
10
Serpins as therapeutics--a potential biologic source for unique protein-based therapeutics.丝氨酸蛋白酶抑制剂作为治疗药物——一种独特的基于蛋白质的治疗药物的潜在生物来源。
Cardiovasc Hematol Disord Drug Targets. 2013 Aug;13(2):89. doi: 10.2174/1871529x11313020001.
本文引用的文献
1
A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention.一项在接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者中进行的病毒丝氨酸蛋白酶抑制剂 Serp-1 的随机对照、2 期临床试验。
Circ Cardiovasc Interv. 2010 Dec;3(6):543-8. doi: 10.1161/CIRCINTERVENTIONS.110.953885. Epub 2010 Nov 9.
2
High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis.超顺磁纳米粒子增强高分辨率磁共振成像测量动脉粥样硬化中的巨噬细胞负荷。
Circulation. 2010 Oct 26;122(17):1707-15. doi: 10.1161/CIRCULATIONAHA.109.891804. Epub 2010 Oct 11.
3
The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics.丝氨酸蛋白酶抑制剂传奇；新型病毒衍生抗炎蛋白免疫治疗药物的研发。
Adv Exp Med Biol. 2009;666:132-56. doi: 10.1007/978-1-4419-1601-3_11.
4
Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.经皮冠状动脉介入治疗后基线炎症标志物、抗血小板治疗与不良心脏事件的关系：来自氯吡格雷减少观察试验事件的分析。
Circ Cardiovasc Interv. 2009 Dec;2(6):503-12. doi: 10.1161/CIRCINTERVENTIONS.109.879312. Epub 2009 Nov 17.
5
Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis.极晚期药物洗脱支架血栓形成患者血管内超声检查结果与血栓抽吸物组织病理学分析的相关性
Circulation. 2009 Aug 4;120(5):391-9. doi: 10.1161/CIRCULATIONAHA.109.854398. Epub 2009 Jul 20.
6
Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries.西罗莫司洗脱支架与紫杉醇洗脱支架植入猪冠状动脉后炎症反应的比较。
Circulation. 2009 Jul 14;120(2):141-9, 1-2. doi: 10.1161/CIRCULATIONAHA.107.730010. Epub 2009 Jun 29.
7
Myxoma viral serpin, Serp-1, inhibits human monocyte adhesion through regulation of actin-binding protein filamin B.黏液瘤病毒丝氨酸蛋白酶抑制剂Serp-1通过调节肌动蛋白结合蛋白细丝蛋白B来抑制人类单核细胞黏附。
J Leukoc Biol. 2009 Mar;85(3):418-26. doi: 10.1189/jlb.0808506. Epub 2008 Dec 3.
8
Different prognostic importance of elevated troponin I after percutaneous coronary intervention in acute coronary syndrome and stable angina pectoris.急性冠状动脉综合征和稳定型心绞痛患者经皮冠状动脉介入治疗后肌钙蛋白I升高的不同预后意义。
Scand Cardiovasc J. 2008 Jun;42(3):214-21. doi: 10.1080/14017430801932824.
9
Pathogen-derived immunomodulatory molecules: future immunotherapeutics?病原体衍生的免疫调节分子：未来的免疫疗法？
Trends Immunol. 2006 Oct;27(10):470-6. doi: 10.1016/j.it.2006.08.002. Epub 2006 Aug 21.
10
Myxoma viral serpin, Serp-1, a unique interceptor of coagulation and innate immune pathways.黏液瘤病毒丝氨酸蛋白酶抑制剂Serp-1，一种凝血和先天免疫途径的独特拦截分子。
Thromb Haemost. 2006 Mar;95(3):499-510. doi: 10.1160/TH05-07-0492.
Zotero 插件